Where can I buy eltp shares?
Shares of ELTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What does eltp stand for?
NORTHVALE, NJ / ACCESSWIRE / August 9, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the first quarter of fiscal year 2020 ended June 30, 2019 (“First Quarter”).
What time does elite pharmaceuticals (eltp) release earnings?
NEW YORK, NY / ACCESSWIRE / February 17, 2021 / Elite Pharmaceuticals, Inc. (OTCQB:ELTP) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 17, 2021 at 11:30 AM Eastern Time.
What is the elite Pharmaceuticals stock forecast for 2023?
The Elite Pharmaceuticals stock forecast is 0.087891805878012 USD for 2023 March 21, Tuesday; and 0.421 USD for 2027 March 21, Sunday. Elite Pharmaceuticals stock forecast, ELTP price prediction: Buy or sell Elite Pharmaceuticals, Inc shares?
About Elite Pharmaceuticals
How has Elite Pharmaceuticals' stock been impacted by COVID-19?
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) segments. The ANDA segment includes generic pharmaceuticals. The NDA segment comprises the branded pharmaceuticals.
How were Elite Pharmaceuticals' earnings last quarter?
Elite Pharmaceuticals' stock was trading at $0.0738 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ELTP shares have decreased by 45.9% and is now trading at $0.0399. View which stocks have been most impacted by COVID-19.
Who are some of Elite Pharmaceuticals' key competitors?
Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) announced its quarterly earnings data on Thursday, June, 14th. The specialty pharmaceutical company reported $0.00 earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.60 million for the quarter.
What other stocks do shareholders of Elite Pharmaceuticals own?
Some companies that are related to Elite Pharmaceuticals include 9 Meters Biopharma (NMTR), Xeris Pharmaceuticals (XERS), TFF Pharmaceuticals (TFFP), Satsuma Pharmaceuticals (STSA), Checkpoint Therapeutics (CKPT), Atossa Therapeutics (ATOS), Inozyme Pharma (INZY), CorMedix (CRMD), Homology Medicines (FIXX), NuCana (NCNA), Sol-Gel Technologies (SLGL), Aeglea BioTherapeutics (AGLE), DURECT (DRRX), scPharmaceuticals (SCPH) and Molecular Templates (MTEM). View all of ELTP's competitors..
What is Elite Pharmaceuticals' stock symbol?
Based on aggregate information from My MarketBeat watchlists, some companies that other Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), iBio (IBIO), PharmaCyte Biotech (PMCB), Ascent Solar Technologies (ASTI), Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), SANUWAVE Health (SNWV) and Sierra Oncology (SRRA)..
How do I buy shares of Elite Pharmaceuticals?
Elite Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELTP."
Signals & Forecast
Shares of ELTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Elite Pharmaceuticals Inc has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation.
Is Elite Pharmaceuticals Inc stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $0.0360 and $0.0350. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level.
Insiders are very positive buying more shares than they are selling in Elite Pharmaceuticals Inc
The Elite Pharmaceuticals Inc stock holds several negative signals and despite the positive trend, we believe Elite Pharmaceuticals Inc will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
About Elite Pharmaceuticals Inc
In the last 100 trades there were 506.04 million shares bought and 462.7 million shares sold. The last trade was done 238 days ago by Dash Barry H who bough 295.57 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 an..
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2022 Financ..
Conference Call Scheduled for Tuesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharma...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year Ended September 30, 2021 ..
Financials for Third Quarter Fiscal Year 2022 Ended December 31, 2021 will be released February 14, 2022 NORTHVALE, NJ / ACCESSWIRE / February 9, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Comp...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2022 Finan..
Conference Call Scheduled for Tuesday, November 16th at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 15, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty phar...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 a..
Financials for Second Quarter Fiscal Year 2022 Ended September 30, 2021 will be released November 15, 2021 NORTHVALE, NJ / ACCESSWIRE / November 9, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Co...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conferenc..
Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / August 16, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company”) (OTCQB:ELTP), a specialty pharmaceu...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Year-End Financial Result..
Conference Call Scheduled for Tuesday, June 15 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 14, 2021 / Elite Pharmaceuticals, Inc. ('Elite' or the "Company') (OTCBB:ELTP), a specialty pharmaceutical...
